| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -525,764 | -445,199 |
| Depreciation and amortization | 62,130 | 49,754 |
| Amortization of debt discounts | 2,295 | 319 |
| Fair value of options issued to officers and directors for services | 0 | 0 |
| Fair value of common shares issued for services | 254,021 | 173,106 |
| Interest capitalized to debt balance | 10,792 | 6,759 |
| Fair value of common shares issued as loan incentives | 5,900 | 5,900 |
| Fair value of warrants issued for refunds | 0 | - |
| Accounts receivable | 47,618 | 6,123 |
| Inventories | -1,716 | 23,136 |
| Prepaid expenses and other assets | -69,087 | -75,533 |
| Accounts payable | 32,173 | 141,321 |
| Accounts payable - related parties | 171,984 | 110,585 |
| Accrued expenses and other liabilities | -72,361 | -47,465 |
| Accrued interest - related parties | 106,234 | 71,399 |
| Deferred revenue | -101,253 | -71,853 |
| Net cash used in operating activities | -30,664 | 40,900 |
| Purchases of property and equipment | 6,000 | 0 |
| Purchases of intangibles | 50,000 | 50,000 |
| Cash acquired in docsun transaction | 0 | 0 |
| Net cash used in investing activities | -56,000 | -50,000 |
| Note and loan payments | 70,266 | 23,592 |
| Increase in note and loan balances | 147,507 | 30,000 |
| Increase in note and loan balances - related parties | 0 | 0 |
| Net cash provided by financing activities | 77,241 | 6,408 |
| Net effect of exchange rate fluctuations | -2,034 | -9,256 |
| Net decrease in cash and cash equivalents | -11,457 | -11,948 |
| Cash and cash equivalents at beginning of period | 58,404 | - |
| Cash and cash equivalents at end of period | 46,947 | - |
BIOREGENX, INC. (BRGX)
BIOREGENX, INC. (BRGX)